Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Actelion Ltd    ATLN   CH0010532478

Delayed Quote. Delayed  - 08/31 05:31:45 pm
163.7 CHF   -1.44%
08:09aACTELION LTD : The calm spell can be taken advantage of to put on ne..
08/22 ACTELION : completes first-line share purchase program
08/16 ACTELION : receives Swissmedic approval for Uptravi (selexipag) for ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion Ltd
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.

It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs.

The company's portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

It has treatments for specialist diseases, including Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides in patients with cutaneous T-cell lymphoma.

The company products include Tracleer (bosentan), Zavesca (miglustat), Ventavis (iloprost), Veletri (epoprostenol for injection), Valchlor and Opsumit (macitentan).

Actelion was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Sales per Businesses
20142015Delta
CHF (in Million)%CHF (in Million)%
Drugs1,958100%2,045100% +4.45%
Sales per Regions
20142015Delta
CHF (in Million)%CHF (in Million)%
United States879.2444.9%1,02650.1% +16.64%
Europe687.8235.1%633.2031% -7.94%
Other360.5218.4%167.868.2% -53.44%
Switzerland30.301.5%28.391.4% -6.32%
Japan--190.069.3%-
Managers
NameAgeSinceTitle
Jean-Paul Clozel611997Chief Executive Officer & Executive Director
Jean-Pierre Garnier682011Chairman
Otto Schwarz612008Chief Operating Officer & Executive Vice President
André C. Muller, MBA532013Chief Financial Officer & Executive Vice President
Martine Clozel, MD611997Chief Scientific Officer & Senior Vice President
Guy Braunstein MD, PhD602009Executive VP & Head-Global Clinical Development
Michael Jacobi, PhD632009Independent Non-Executive Director
Jean Pierre Malo CFA, MBA622004Independent Non-Executive Director
Juhani Anttila62-Independent Non-Executive Director
Robert J. Bertolini, CPA53-Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 107,761,427 89,519,496 83.1% 8,943,000 8.3% 83.1%
Shareholders
NameEquities%
Rudolf Maag, MBA 5,467,305 4.79%
Jean-Paul Clozel 5,418,507 4.75%
Wellington Management Co. LLP 3,202,870 2.81%
Fidelity Management & Research Co. 2,979,964 2.61%
Actelion Ltd. 2,857,792 2.50%
UBS AG (Investment Management) 2,156,004 1.89%
Artisan Partners LP 2,065,661 1.81%
BlackRock Investment Management (UK) Ltd. 2,065,321 1.81%
The Vanguard Group, Inc. 1,960,426 1.72%
Bellevue Asset Management AG 1,702,164 1.49%
Holdings
NameEquities%Valuation
Actelion Ltd (ATLN) 2,857,7922.50%508,308,176 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ACTELION LTD17.62%18 198
AMGEN, INC.5.19%127 790
GILEAD SCIENCES, INC.-23.00%102 828
CELGENE CORPORATION-10.64%82 953
REGENERON PHARMACEUTIC..-27.20%41 614
VERTEX PHARMACEUTICALS..-23.87%23 737
MEDIVATION INC66.24%13 334
GENMAB A/S18.26%9 868
HUALAN BIOLOGICAL ENGI..--.--%5 488
TONGHUA DONGBAO PHARMA..-83.39%4 821
TESARO INC64.55%4 422
NEUROCRINE BIOSCIENCES..-13.08%4 266
INTERCEPT PHARMACEUTIC..0.88%3 726
JUNO THERAPEUTICS INC-28.29%3 335
BEIJING SL PHARMACEUTI..--.--%3 235
CHINA BIOLOGIC PRODUCT..-22.08%2 985
KITE PHARMA INC-4.72%2 912
BIOCON LTD71.94%2 723
ULTRAGENYX PHARMACEUTI..-40.44%2 635
EXELIXIS, INC.95.74%2 543
PEPTIDREAM INC13.32%2 495
Sector Bio Therapeutic Drugs
Actelion Ltd : Connections
CFA Institute
Alzheon, Inc.
Cerenis Therapeutics, Inc.
Martin Hilti Family Trust
Avalon Advisors LLC
Newman's Own Foundation
Max Planck Institute For Biophysical Chemistry
Actelion Pharmaceuticals UK Ltd.
Actelion Pharmaceuticals Hellas SA
Hilti AG
Actelion Pharmaceuticals Italia SRL
Hilti Martin Family Trust
Actelion Pharmaceuticals Japan Ltd.
Society of Financial Analysts of Houston
ArgYou AG
ValCrea AG
Actelion Pharmaceuticals Korea Ltd.
Actelion Pharmaceuticals Sverige AB
Anttila & Co. Advisors
Actelion Clinical Research, Inc.
Company contact information
16 Gewerbestrasse
CH-4123 Allschwil, Basel-Landschaft
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
- SMI /
Stock Exchange Codes
- ISIN Code :  CH0010532478
- Bloomberg Code :  ATLN:VX
- Reuters Code :  ATLN.VX
- Datastream Code :  S:ATLN
© 2016 People , Fundamentals and Ownership    © 2016 Cofisem